To our knowledge, this is the first demonstration that HMG-CoA reductase inhibitors such as simvastatin may be effective in decreasing the degree of myocarditis by inhibiting MMPs activation, thus suggesting the interest for clinical studies. The gene discussed is HMGCR; the disease is myocarditis.